Chronic Myelomonocytic Leukemia (DBCOND0028572)

Identifiers

Synonyms

Leukemia Myelomonocytic Chronic / Chronic Myelomonocytic Leukemia (CMML) / Chronic myelomonocytic leukaemia / CMML / Chronic myelomonocytic leukemia / Leukemia, Myelomonocytic, Chronic / Chronic myelomonocytic leukemia not having achieved remission / Chronic myelomonocytic leukemia (morphologic abnormality) / Chronic myelomonocytic leukemia (disorder) / Monocytic leukemia, chronic / Chronic monocytic leukemia / Monocytic leukaemia, chronic / Leukaemia monocytic chronic / Leukemia monocytic chronic / Chronic monocytic leukaemia / Leukemia, Monocytic, Chronic

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Azacitidine	A pyrimidine nucleoside analogue used to treat certain subtypes of myelodysplastic syndrome.	DNA (cytosine-5)-methyltransferase 1target Cytidine deaminaseenzyme DNAtarget RNAtarget
Cedazuridine	A cytidine deaminase inhibitor coadministered with the hypomethylating agent decitabine for the treatment of variable forms of myelodysplastic syndrome (MDS).	Cytidine deaminasetarget
Decitabine	A chemotherapeutic pyrimidine nucleoside analogue used for the treatment of myelodysplastic syndromes (MDS) by inducing DNA hypomethylation and corresponding alterations in gene expression.	DNAtarget DNA (cytosine-5)-methyltransferase 1target Deoxycytidine kinaseenzyme UMP-CMP kinaseenzyme Nucleoside diphosphokinaseenzyme Cytidine deaminaseenzyme DNA (cytosine-5)-methyltransferase 3Atarget DNA (cytosine-5)-methyltransferase 3Btarget Sodium/nucleoside cotransporter 1transporter Histone deacetylasetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05969821	Clonal Hematopoiesis of Immunological Significance	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT02546284	Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)	No drug interventions	treatment	1	completed
NCT05048498	Pharmacokinetics, Tolerability and Safety of NEX-18a	Azacitidine	treatment	1	completed
NCT00528983	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia	No drug interventions	treatment	1	completed
NCT03613532	Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	Azacitidine Busulfan Cedazuridine Decitabine Fludarabine Venetoclax	treatment	1	recruiting
NCT03922100	Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML	No drug interventions	treatment	1 / 2	recruiting
NCT05665530	A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies	Venetoclax Zanubrutinib	treatment	1	recruiting
NCT01613976	A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients	Panobinostat	treatment	1	completed
NCT01842646	Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)	No drug interventions	treatment	2	completed
NCT00664677	Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia	No drug interventions	treatment	1	terminated
NCT01736683	Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)	No drug interventions	treatment	2	completed
NCT04409639	Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations	No drug interventions	treatment	2	recruiting
NCT04217720	SNS-301 Monotherapy in High Risk MDS and CMML	No drug interventions	treatment	2	withdrawn
NCT02147873	Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL	No drug interventions	treatment	2	terminated
NCT04603001	Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations	No drug interventions	treatment	1	active_not_recruiting
NCT06563804	A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML	No drug interventions	treatment	1 / 2	not_yet_recruiting
NCT02749708	Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome	No drug interventions	treatment	1	terminated
NCT02727803	Personalized NK Cell Therapy in CBT	No drug interventions	treatment	2	recruiting
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	No drug interventions	supportive_care	2	completed
NCT00015990	Thalidomide in Treating Patients With Myelodysplastic Syndrome	No drug interventions	treatment	2	completed
NCT03912064	A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT	No drug interventions	treatment	1	active_not_recruiting
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	No drug interventions	supportive_care	Not Available	completed
NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	No drug interventions	treatment	1	suspended
NCT05218902	A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)	No drug interventions	Not Available	Not Available	completed
NCT05246384	Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia	No drug interventions	treatment	1 / 2	withdrawn
NCT01338987	Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation	Busulfan Cyclophosphamide Fludarabine Leuprolide Methotrexate Tacrolimus	treatment	2	completed
NCT01908387	Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms	Azacitidine	treatment	1	terminated
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Cyclophosphamide Cyclosporine Filgrastim Fludarabine Mycophenolate mofetil Mycophenolic acid Treosulfan	treatment	2	recruiting
NCT03683433	Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation	Azacitidine Doxazosin Enasidenib Isopropyl alcohol	treatment	2	recruiting
NCT04708054	Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS	Busulfan Cladribine Fludarabine Thiotepa Tromethamine Venetoclax	treatment	2	recruiting
NCT03268954	Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)	Azacitidine Pevonedistat	treatment	3	active_not_recruiting
NCT00006251	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT02891551	An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands	No drug interventions	Not Available	Not Available	completed
NCT02610777	An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)	Azacitidine Pevonedistat	treatment	2	completed
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT01350947	A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia	Azacitidine	treatment	2	completed
NCT00005845	Tipifarnib in Treating Patients With Myelodysplastic Syndromes	Tipifarnib	treatment	1	completed
NCT00002798	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Aldesleukin Asparaginase Escherichia coli Aspartic acid Busulfan Cyclophosphamide Cytarabine Daunorubicin Dexamethasone Etoposide Filgrastim Fludarabine Hydrocortisone Idarubicin Methotrexate Tioguanine	treatment	3	completed
NCT02085798	Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)	No drug interventions	Not Available	Not Available	completed
NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	Aldesleukin Busulfan Fludarabine Natural Killer Cell	treatment	1 / 2	completed
NCT03814005	A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems	Azacitidine Pevonedistat	other	1	completed
NCT05031897	Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant	Cyclophosphamide Fludarabine Melphalan Mycophenolate mofetil Tacrolimus	treatment	2	recruiting
NCT00095797	XK469R in Treating Patients With Refractory Hematologic Cancer	No drug interventions	treatment	1	completed
NCT06355583	Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial	No drug interventions	prevention	2	not_yet_recruiting
NCT04802161	Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes	Cytarabine Daunorubicin Pomalidomide	treatment	2	suspended
NCT06218628	Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition	Pacritinib Talazoparib	treatment	1	recruiting
NCT01749111	Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis	Cyclophosphamide Methotrexate	prevention	3	terminated
NCT04473911	Haplo Peripheral Blood Sct In GVHD Prevention	Cyclophosphamide Fludarabine KRN-7000 Melphalan Mycophenolate mofetil Mycophenolic acid Sirolimus	treatment	1	active_not_recruiting
NCT03047993	Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome	Azacitidine Telaglenastat	treatment	1 / 2	completed
NCT03404193	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome	Decitabine Venetoclax	treatment	2	active_not_recruiting
NCT04358393	A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS	Alrizomadlin Azacitidine	treatment	1 / 2	recruiting
NCT05823571	Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients	Itacitinib	treatment	1	recruiting
NCT03175978	IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome	Methotrexate	treatment	1 / 2	terminated
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT03588078	Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine	Azacitidine Eprenetapopt	treatment	1 / 2	unknown_status
NCT03280888	Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)	No drug interventions	Not Available	Not Available	unknown_status
NCT03722407	Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion	Ruxolitinib	treatment	2	active_not_recruiting
NCT05739409	LILRB4 STAR-T Cell Therapy for Monocytic Leukemia	No drug interventions	treatment	Not Available	not_yet_recruiting
NCT00852709	Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Clofarabine Cyclophosphamide	treatment	1	terminated
NCT00136409	A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)	No drug interventions	treatment	2	completed
NCT05883956	A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia	Azacitidine Cedazuridine Decitabine	treatment	3	active_not_recruiting
NCT01484015	Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia	Cefepime	treatment	1	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT01928537	Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine	Rigosertib	treatment	3	completed
NCT01831232	Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes	Cytarabine Idarubicin Pravastatin	treatment	Not Available	completed
NCT04160052	Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome	Azacitidine Venetoclax	treatment	1 / 2	recruiting
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	No drug interventions	treatment	2	completed
NCT01812252	Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant	Azacitidine Decitabine	treatment	2	completed
NCT01305200	Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant	Calcium Phosphate	supportive_care	3	completed
NCT05641259	A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML	Azacitidine	treatment	1	recruiting
NCT02907359	Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs	Guadecitabine	treatment	3	completed
NCT00351975	Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases	No drug interventions	treatment	1	completed
NCT03383575	Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome	Azacitidine Enasidenib	treatment	2	recruiting
NCT04761770	Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders	No drug interventions	treatment	2	active_not_recruiting
NCT00005942	Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy	No drug interventions	treatment	1 / 2	completed
NCT03363399	Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes	No drug interventions	Not Available	Not Available	completed
NCT06439199	Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT01083706	Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant	Azacitidine	treatment	2	completed
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Azacitidine Cusatuzumab	treatment	2	withdrawn
NCT03964506	Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant	No drug interventions	treatment	0	recruiting
NCT00509249	Aflibercept in Treating Patients With Myelodysplastic Syndromes	No drug interventions	treatment	2	terminated
NCT00719836	A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies	Pacritinib	treatment	1 / 2	completed
NCT02564536	Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)	Decitabine Pacritinib	treatment	1	withdrawn
NCT00079313	Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia	No drug interventions	treatment	2	completed
NCT01384513	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies	Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00397813	Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	No drug interventions	treatment	2	completed
NCT03358719	DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia	Cancer/testis antigen 1 Carboxymethylcellulose Decitabine Hiltonol Lysine Nivolumab Polyinosinic-polycytidylic acid Rasdegafusp alfa	treatment	1	completed
NCT04888741	Methods of T Cell Depletion Trial (MoTD)	Antithymocyte immunoglobulin (rabbit) Cyclophosphamide Cyclosporine Mycophenolate mofetil Sirolimus	prevention	2	recruiting
NCT03746041	A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes	Abaloparatide Bevacizumab	treatment	1	completed
NCT01048034	Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)	Azacitidine Erythropoietin	treatment	2	completed
NCT06071624	Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.	No drug interventions	treatment	1	recruiting
NCT01165996	Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome	2'-Deoxycytidine Decitabine	treatment	1 / 2	completed
NCT04730258	A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML	Azacitidine Ocifisertib	treatment	1 / 2	recruiting
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	No drug interventions	treatment	1 / 2	completed
NCT02210858	Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders	Tipifarnib	treatment	1 / 2	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT03813186	Effect of Food on Blood Levels of ASTX727	Cedazuridine Decitabine	basic_science	1	completed
NCT01133886	Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure	Decitabine	treatment	2	unknown_status
NCT00313586	Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	No drug interventions	treatment	2	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT03333486	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer	Cyclophosphamide Fludarabine	treatment	2	active_not_recruiting
NCT03672539	Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome	Cytarabine Daunorubicin Gemtuzumab ozogamicin	treatment	2	recruiting
NCT01757639	Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	Ipilimumab	treatment	1	completed
NCT00761722	Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma	Azacitidine	treatment	1	completed
NCT05970822	Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML	Azacitidine	treatment	1	recruiting
NCT03862157	Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Azacitidine Pevonedistat Venetoclax	treatment	1 / 2	active_not_recruiting
NCT04609826	A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	No drug interventions	treatment	1	active_not_recruiting
NCT05201066	Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.	Azacitidine Cedazuridine Decitabine Sabatolimab Spartalizumab Venetoclax	treatment	2	recruiting
NCT03850574	Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Tuspetinib Venetoclax	treatment	1 / 2	recruiting
NCT00027820	Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT01772420	Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia	Eltrombopag Lenalidomide	treatment	2	completed
NCT00843882	Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia	Erythropoietin Lenalidomide	treatment	3	active_not_recruiting
NCT02556931	Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01251627	Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia	Decitabine	treatment	2	completed
NCT00588991	Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders	No drug interventions	treatment	1	active_not_recruiting
NCT02472691	Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT	Azacitidine Lenalidomide	treatment	2	completed
NCT06159491	Pacritinib in CMML	Azacitidine Pacritinib	treatment	1 / 2	recruiting
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT00025662	Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS	No drug interventions	treatment	2	completed
NCT05364762	Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants	Cyclophosphamide Itacitinib Tacrolimus	prevention	2	recruiting
NCT01101880	Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm	Clofarabine Clofarabine Cytarabine Filgrastim	treatment	2	completed
NCT01885689	Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia	No drug interventions	treatment	2	active_not_recruiting
NCT00510289	Sorafenib in Myelodysplastic Syndrome	No drug interventions	treatment	2	terminated
NCT01957644	Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML	No drug interventions	treatment	1	terminated
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	No drug interventions	supportive_care	2	terminated
NCT03734601	Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation	No drug interventions	treatment	2	completed
NCT04266301	Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)	No drug interventions	treatment	3	active_not_recruiting
NCT04842604	Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML	No drug interventions	treatment	3	completed
NCT02807272	Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia	No drug interventions	treatment	2	completed
NCT01169012	PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	No drug interventions	basic_science	1	completed
NCT00171912	Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	No drug interventions	treatment	2	completed
NCT06111612	Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement	No drug interventions	Not Available	Not Available	recruiting
NCT03289910	Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	No drug interventions	treatment	2	active_not_recruiting
NCT01146210	Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	No drug interventions	Not Available	Not Available	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	completed
NCT01773395	GVAX vs. Placebo for MDS/AML After Allo HSCT	No drug interventions	treatment	2	terminated
NCT01595295	Registry on Hypomethylating Agents in Myeloid Neoplasms	No drug interventions	Not Available	Not Available	completed
NCT04522895	IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT	No drug interventions	treatment	2	active_not_recruiting
NCT00283114	A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome	No drug interventions	treatment	1	completed
NCT04655755	Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	No drug interventions	treatment	1 / 2	recruiting
NCT03999723	Combining Active and Passive DNA Hypomethylation	No drug interventions	treatment	2	recruiting
NCT00098423	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes	No drug interventions	treatment	1	completed
NCT03018223	Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT	No drug interventions	prevention	1	completed
NCT00357708	Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases	No drug interventions	treatment	1	completed
NCT00067808	Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)	Decitabine	treatment	2	completed
NCT02760238	Myeloproliferative Neoplasms (MPNs) Patient Registry	No drug interventions	Not Available	Not Available	recruiting
NCT04146038	Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	No drug interventions	treatment	2	completed
NCT03418038	Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia	No drug interventions	treatment	2	recruiting
NCT03072043	Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms	No drug interventions	treatment	1 / 2	completed
NCT02649764	Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	No drug interventions	treatment	1	completed
NCT03306264	Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML	No drug interventions	treatment	3	completed
NCT00708721	Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia	No drug interventions	treatment	1 / 2	terminated
NCT00113321	Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure	No drug interventions	treatment	2	terminated
NCT01098084	Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)	No drug interventions	Not Available	2	completed
NCT00101179	MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	No drug interventions	treatment	1	completed
NCT01926587	Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine	No drug interventions	treatment	1 / 2	completed
NCT00038051	Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies	No drug interventions	treatment	1	completed
NCT02268253	Tagraxofusp (SL-401) in Patients With CMML or MF	No drug interventions	treatment	2	completed
NCT00392353	Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	No drug interventions	treatment	1 / 2	active_not_recruiting
NCT01894477	Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia	No drug interventions	treatment	2	unknown_status
NCT00008177	Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00946647	A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).	No drug interventions	treatment	1 / 2	completed
NCT01464047	Korean Post-marketing Surveillance for Sprycel®	No drug interventions	Not Available	Not Available	completed
NCT03602898	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	No drug interventions	treatment	2	withdrawn
NCT00357305	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders	No drug interventions	treatment	1	completed
NCT00462605	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia	No drug interventions	treatment	2	completed
NCT01664897	Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	No drug interventions	treatment	2	completed
NCT02935361	Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed	No drug interventions	treatment	1 / 2	active_not_recruiting
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT01519011	Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine	No drug interventions	treatment	1	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	No drug interventions	treatment	Not Available	completed
NCT03146871	Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent	No drug interventions	treatment	2	terminated
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	No drug interventions	treatment	Not Available	completed
NCT01010256	The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia	No drug interventions	Not Available	Not Available	terminated
NCT05107856	PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies	No drug interventions	treatment	1	terminated
NCT00299156	Oral Clofarabine Study in Patients With Myelodysplastic Syndrome	No drug interventions	treatment	2	completed
NCT06523556	Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia	No drug interventions	treatment	1 / 2	not_yet_recruiting
NCT02367456	A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients	No drug interventions	treatment	1	completed
NCT06001385	HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis	No drug interventions	treatment	2	recruiting
NCT00988715	Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	No drug interventions	treatment	1	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT03263637	Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies	No drug interventions	treatment	1	completed
NCT05807932	Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML	No drug interventions	treatment	1 / 2	recruiting
NCT05209152	AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia	No drug interventions	treatment	1	completed
NCT01241500	Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts	No drug interventions	treatment	3	completed
NCT00038675	Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate	Imatinib	treatment	Not Available	completed
NCT04093570	A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers	No drug interventions	treatment	2	enrolling_by_invitation
NCT01139970	Veliparib and Temozolomide in Treating Patients With Acute Leukemia	No drug interventions	treatment	1	active_not_recruiting
NCT06566742	A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.	No drug interventions	treatment	2	not_yet_recruiting
NCT00744536	Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS	No drug interventions	treatment	2	completed
NCT05233618	Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)	No drug interventions	treatment	1	recruiting
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT01872819	Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay	No drug interventions	treatment	Not Available	completed
NCT02553941	Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome	No drug interventions	treatment	1	completed
NCT01404741	5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)	No drug interventions	treatment	2	completed
NCT04167917	NTX-301 in MDS/AML	No drug interventions	treatment	1	recruiting
NCT03128034	211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia	No drug interventions	treatment	1 / 2	suspended
NCT00084916	CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase	No drug interventions	treatment	2	completed
NCT01620216	Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia	No drug interventions	treatment	2	terminated
NCT00589316	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome	No drug interventions	treatment	1	terminated
NCT00039416	Imatinib Mesylate in Treating Patients With Myelofibrosis	Imatinib	treatment	2	completed
NCT00096122	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	No drug interventions	treatment	1 / 2	completed
NCT00451048	Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia	No drug interventions	treatment	2	completed
NCT03066648	Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS	No drug interventions	treatment	1	completed
NCT01834248	DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia	No drug interventions	treatment	1	completed
NCT01368757	Lenalidomide in Patients With Chronic Myelomonocytic Leukemia	No drug interventions	treatment	1 / 2	unknown_status
NCT04239157	A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia	No drug interventions	treatment	2	recruiting
NCT00387426	Sunitinib in Treating Patients With Idiopathic Myelofibrosis	No drug interventions	treatment	2	terminated
NCT03670966	211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome	No drug interventions	treatment	1 / 2	suspended
NCT03526666	Ascorbic Acid Levels in MDS, AML, and CMML Patients	No drug interventions	Not Available	Not Available	completed
NCT00119366	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	No drug interventions	treatment	2	terminated
NCT04937166	A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies	No drug interventions	treatment	1	recruiting
NCT00860574	Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia	No drug interventions	treatment	2	completed
NCT00052520	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	No drug interventions	treatment	1 / 2	completed
NCT02397720	Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia	No drug interventions	treatment	2	completed
NCT03096782	Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma	No drug interventions	treatment	2	completed
NCT01629082	Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia	No drug interventions	treatment	1	completed
NCT00012376	Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer	No drug interventions	treatment	1	completed
NCT01522976	Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia	No drug interventions	treatment	2	active_not_recruiting
NCT05600894	Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm	No drug interventions	treatment	2	recruiting
NCT01053494	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	No drug interventions	supportive_care	Not Available	completed
NCT05024994	A Study of E7820 in People With Bone Marrow (Myeloid) Cancers	No drug interventions	treatment	2	active_not_recruiting
NCT02684162	Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant	No drug interventions	treatment	2	active_not_recruiting
NCT01398462	Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients	No drug interventions	treatment	1	completed
NCT02201329	Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	No drug interventions	treatment	1	completed
NCT05038592	Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia	No drug interventions	treatment	1 / 2	recruiting
NCT02841540	A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes	No drug interventions	treatment	1	terminated
NCT03040401	A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)	No drug interventions	treatment	1 / 2	unknown_status
NCT02129101	Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies	No drug interventions	treatment	1	completed
NCT05895201	High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD	No drug interventions	treatment	1 / 2	withdrawn
NCT00087204	Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	No drug interventions	treatment	1	completed
NCT02566304	Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	No drug interventions	treatment	2	active_not_recruiting
NCT04980404	Inqovi Maintenance Therapy in Myeloid Neoplasms	No drug interventions	treatment	1	recruiting
NCT01300572	Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	No drug interventions	treatment	1	completed
NCT05428969	A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies	No drug interventions	treatment	1 / 2	recruiting
NCT05456269	A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS	No drug interventions	treatment	1	withdrawn
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	No drug interventions	supportive_care	2	completed
NCT00255346	Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)	No drug interventions	treatment	2	completed
NCT02960646	Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	No drug interventions	treatment	1	completed
NCT03493646	Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486	No drug interventions	treatment	2	completed
NCT04581512	Study to Evaluate the Safety and Tolerability of EP0042	No drug interventions	treatment	1 / 2	recruiting
NCT03515512	IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation	No drug interventions	treatment	1	completed
NCT04953312	Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)	No drug interventions	diagnostic	Not Available	not_yet_recruiting
NCT06543381	Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant	No drug interventions	treatment	1	recruiting
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	No drug interventions	treatment	2	completed
NCT02190695	Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS	No drug interventions	treatment	2	completed
NCT05636514	Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS	No drug interventions	treatment	1	recruiting
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	No drug interventions	supportive_care	2	completed
NCT01760655	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	No drug interventions	treatment	2	completed
NCT00074750	Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)	No drug interventions	treatment	1	terminated
NCT00809250	Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation	No drug interventions	treatment	1	completed
NCT00381550	3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia	No drug interventions	treatment	2	completed
NCT02666950	WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	No drug interventions	treatment	2	completed
NCT00885508	A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q	No drug interventions	treatment	2	unknown_status
NCT06085638	Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia	No drug interventions	treatment	1 / 2	withdrawn
NCT04493138	Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations	No drug interventions	treatment	1 / 2	recruiting
NCT00109538	Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)	No drug interventions	treatment	3	terminated
NCT06267898	Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML	No drug interventions	Not Available	Not Available	completed
NCT05184842	Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML	Decitabine Venetoclax	treatment	2	recruiting
NCT04806906	Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients	Azacitidine	treatment	2	active_not_recruiting
NCT01261312	SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)	No drug interventions	other	1 / 2	completed
NCT04372433	IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML	No drug interventions	treatment	1	active_not_recruiting
NCT02323178	A Study of Eltrombopag in Patients With CMML and Thrombocytopenia	No drug interventions	treatment	1 / 2	completed
NCT02581007	Reduced Intensity Conditioning Transplant Using Haploidentical Donors	No drug interventions	treatment	2	completed
NCT02418000	A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations	No drug interventions	treatment	1 / 2	terminated
NCT04139434	Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML	No drug interventions	treatment	1	active_not_recruiting
NCT02193958	Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies	No drug interventions	treatment	1 / 2	completed
NCT05153226	GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG	No drug interventions	prevention	3	recruiting